K. Ethirajulu

发表

MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.

G. Cruciani, E. Carosati, B. De Boeck, 2005, Journal of medicinal chemistry.

Arthritis and C-fms for the Treatment of Rheumatoid Sb1578, a Novel Inhibitor of Jak2, Flt3

J. Wood, B. Madan, K. Goh, 2022 .

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

Microsoft Word-70929949-file00.docx

Changyong Hu, P. Yeo, K. Ethirajulu, 2011 .

Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics

Haishan Wang, V. Pilla Reddy, K. Sangthongpitag, 2011, Drug Metabolism and Disposition.

Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

J. Wood, B. Goh, W. Yong, 2011, Molecular Cancer Therapeutics.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.

J. Connolly, S. Maurer-Stroh, J. Low, 2014, Vaccine.

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

A. Poulsen, A. William, B. Dymock, 2011, Leukemia.

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

J. Wood, A. William, B. Dymock, 2012, Leukemia.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J. Shah, J. Wood, P. Mclaughlin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

R. Gomeni, A. Matter, P. Yeo, 2019, Clinical and translational science.

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.

B. Goh, R. Soo, W. Yong, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthr

J. Wood, A. Poulsen, A. William, 2012, Journal of medicinal chemistry.

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

D. Lye, B. J. Hanson, S. G. Seah, 2022, Infectious Diseases and Therapy.

Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

G. Wilding, H. Kantarjian, G. Garcia-Manero, 2010 .

Molecular Cancer Therapeutics SB 939 , a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Z. Bonday, J. Wood, Haishan Wang, 2010 .

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

John E. Connolly, D. Lye, B. J. Hanson, 2022, Infectious Diseases and Therapy.

2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1.

Chang Kai Soh, Kay Lin Goh, Z. Bonday, 2012, Bioorganic & medicinal chemistry letters.

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-

J. Wood, A. Poulsen, Meredith Williams, 2012, Journal of medicinal chemistry.

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

J. Wood, K. Goh, K. Ethirajulu, 2012, Blood Cancer Journal.

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Z. Bonday, J. Wood, Haishan Wang, 2010, Molecular Cancer Therapeutics.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho

Anders Poulsen, Stéphanie Blanchard, Harish Nagaraj, 2011, Journal of medicinal chemistry.

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

H. Deeg, J. Wood, Z. Estrov, 2009 .

Chemical Therapeutics VS-5584 , a Novel and Highly Selective PI 3 K / mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2013 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.

Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours.

W. Messersmith, D. Virshup, B. Madan, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.

D. Virshup, B. Madan, Jeffrey Hill, 2017 .

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

A. Barrett, P. MacAry, P. Hutchinson, 2020, bioRxiv.

KINETIC STUDIES OF HETEROGENEOUSLY CATALYZED TRANSESTERIFICATION OF COTTONSEED OIL TO BIODIESEL

K. Ethirajulu, N. Jaya, 2011 .

416 The oral HDAC inhibitor SB939 shows activity in in vitro and in vivo models of acute myeloid leukemia

J. Wood, Haishan Wang, K. Goh, 2010 .

nonaene ( SB 1578 ) , a Potent Inhibitor of Janus Kinase 2 / Fms-LikeTyrosine Kinase-3 ( JAK 2 / FLT 3 ) for the Treatment of Rheumatoid Arthritis

Anders Poulsen, Harish Nagaraj, Evelyn Tan, 2012 .

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

S. Faria, J. Wood, P. Mclaughlin, 2009 .

Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells

R. Greil, R. Weichselbaum, G. Prendergast, 2011, Molecular Cancer Therapeutics.

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

J. Wood, Haishan Wang, S. Pettersson, 2010, Molecular Cancer Therapeutics.

Supporting Information: Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl- ethoxy)-14,19-dioxa-5,7,26-triaza- tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment o

Harish, J. Wood, Meredith Williams, 2011 .

Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies.

B. Goh, R. Soo, W. Yong, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

B. Goh, R. Soo, W. Yong, 2008 .

This information is current as Arthritis and c-Fms for the Treatment of Rheumatoid SB 1578 , a Novel Inhibitor of JAK 2 , FLT 3 , Dymock and

B. Madan, K. Goh, K. Ethirajulu, 2012 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.